» Articles » PMID: 3997072

Natural History of Chronic Hepatitis B Virus Infection in Taiwan: Studies of Hepatitis B Virus DNA in Serum

Overview
Journal Hepatology
Specialty Gastroenterology
Date 1985 May 1
PMID 3997072
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatitis B virus DNA (HBV DNA) in serum was measured by a Spot hybridization technique in a consecutive series of 79 cases with chronic HBV infection from Taiwan. HBV DNA was found in 96.3% (52/54) of HBeAg-positive, 66% (2/3) with neither HBeAg or anti-HBe and in 63.6% (14/22) of anti-HBe positive patients. The levels of HBV DNA in the HBe-Ag-positive patients were significantly higher than in the anti-HBe positive patients (median, 944 vs. 58 pg per ml, p less than 0.001). The mean ages increased from 28.7 years for the cases with high levels of HBV DNA, to 34.7 years for those with low levels (p less than 0.01) and to 41.0 years in those without HBV DNA in serum (p less than 0.05 when compared with those with low level of HBV DNA). Ninety per cent of patients (27/30) with high levels of HBV DNA showed only minor hepatic inflammatory activity, as did 91% (10/11) of those without HBV DNA. In contrast, histologic signs of chronic active hepatitis or chronic lobular hepatitis were demonstrated in 76% of cases (29/38) with low levels of HBV DNA. These data are consistent with the hypothesis that liver damage occurs during the period of clearance of hepatocytes supporting HBV replication, and are inconsistent with the view that HBV may be directly cytopathic. Thus, the natural history of chronic HBV infection may be divided into three phases.(ABSTRACT TRUNCATED AT 250 WORDS)

Citing Articles

Existing problems and new advice on stage criteria of natural history for chronic hepatitis B.

Xing T BMC Infect Dis. 2025; 25(1):17.

PMID: 39754052 PMC: 11699759. DOI: 10.1186/s12879-024-10408-x.


Risk factors for significant histological changes in both HBeAg positive and negative treatment-naive chronic hepatitis B with persistently normal alanine aminotransferase level.

Xu C, Zhao Y, Chen H, Ren W, Yang X, Zheng W BMC Infect Dis. 2024; 24(1):1120.

PMID: 39379873 PMC: 11460226. DOI: 10.1186/s12879-024-10015-w.


The efficacy and safety of pegylated interferon α-2b-based immunotherapy for inactive hepatitis B surface antigen carriers.

Ning H, Li K, Peng Z, Jin H, Zhao H, Shang J Eur J Gastroenterol Hepatol. 2023; 35(10):1216-1223.

PMID: 37577817 PMC: 10756704. DOI: 10.1097/MEG.0000000000002627.


Acoustic radiation force impulse predicts long-term outcomes in a large-scale cohort: High liver cancer, low comorbidity in hepatitis B virus.

Tai J, Harrison A, Chen H, Hsu C, Hsu T, Chen C World J Gastroenterol. 2023; 29(14):2188-2201.

PMID: 37122600 PMC: 10130974. DOI: 10.3748/wjg.v29.i14.2188.


Long-term prognosis and the need for histologic assessment of chronic hepatitis B in the serological immune-tolerant phase.

Yoo J, Park S, Moon J, Lee Y, Lee H, Lee J Clin Mol Hepatol. 2023; 29(2):482-495.

PMID: 36603573 PMC: 10121308. DOI: 10.3350/cmh.2022.0322.